BioNTech reported an EPS of -$0.14, missing the estimated EPS of $0.75, indicating a significant decline from the previous year's EPS of $0.81.The company exceeded revenue expectations with $1.78 billion compared to the estimated $1.09 billion, largely due to its partnership with Bristol-Myers Squibb.BioNTech's financial stability is underscored by a low debt-to-equity ratio of 0.015 and a strong current ratio of 8.61.BioNTech SE (NASDAQ: BNTX) is a leading biotechnology company known for its innovative wor ...